New and late-breaking data highlighted at 2023 San Antonio Breast Cancer Symposium®
Fort Myers, Fla., December 8, 2023 – Florida Cancer Specialists & Research Institute, LLC (FCS) hematologists and medical oncologists are presenting the findings of state-of-the-art breast cancer research conducted at FCS during the 2023 San Antonio Breast Cancer Symposium® this week. This international scientific symposium brings together breast cancer researchers and physicians to present new and late-breaking data and developments in the diagnosis and treatment of breast cancer. FCS oncology experts will join more than 9,500 colleagues from 100 countries with special interest in breast cancer.
“Although breast cancer is the most common cancer in the world, accounting for nearly 13% of all new cancer cases each year, survival rates and overall outcomes have been increasing steadily during the past three decades,” notes FCS President & Managing Physician Lucio N. Gordan, MD. “This is due in large part to treatment advancements developed as a result of clinical trials, including research conducted throughout our statewide practice.”
Manish Patel, MD, FCS Director of Drug Development, is first author of a first-in-human Phase 1 trial utilizing a novel estrogen receptor chimeric degrader in patients with advanced or metastatic breast cancer.
As co-authors of five additional abstracts that include first-in-human Phase 1 and Phase 2 clinical trials, the following FCS hematologists and medical oncologists will participate in poster and oral presentations:
Judy Wang, MD, FCS Associate Director of Drug Development, as co-author of the PMD-026 Phase 1/1b study of patient selection for high RSK2 expression for achieving improved PFS in metastatic breast cancer.
Lowell M. Hart, MD, FACP, co-author of an abstract examining overall survival in elderly patients on Ribociclib and hormonal therapy for HR+/HER2– advanced breast cancer across the MONALEESA-2, -3, and -7 trials.
Cesar Augusto Perez, MD, co-author of a first-in-human global study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients with advanced solid tumors and in combination with fulvestrant in patients with advanced breast cancer and co-author of a first-in-human study of the highly selective PI3Kα inhibitor RLY-5836 in patients with advanced breast cancer and other solid tumors.
Gail Lynn Shaw Wright, MD, FACP, FCCP, co-author of an abstract reporting final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification.
FCS Physician Director of Clinical Research Gustavo A. Fonseca, MD, FACP said, “It is exciting to share the results of our research on a global stage and to know that our work is contributing to the growing numbers of breast cancer survivors, including 4 million American women and men.”
To view all the abstracts presented at SABCS, visit: https://www.sabcs.org/.